Related Experiment Video
Updated: Jun 16, 2026
10:12
A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model
Published on: October 31, 2012
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Torleif Tollefsrud Gjølberg1,2,3,4, Simone Mester5,6,7,8, Gaia Calamera5
1Authera AS, 0349, Oslo, Norway. torleif@authera.bio.
Summary
Targeting the neonatal Fc receptor (FcRn) offers a promising new strategy for treating autoimmune diseases driven by immunoglobulin G (IgG) autoantibodies. This approach aims to eliminate pathogenic IgG, providing hope for various autoimmune conditions.
Area of Science:
- Immunology
- Autoimmunity
- Pharmacology
Background:
- Autoimmune diseases are common, disproportionately affecting women, and characterized by self-reactive antibodies.
- Pathogenic immunoglobulin G (IgG) autoantibodies drive disease by attacking healthy cells, necessitating targeted therapies.
- The neonatal Fc receptor (FcRn) regulates IgG and albumin levels by preventing their degradation.
Purpose of the Study:
- To review the role of the neonatal Fc receptor (FcRn) in regulating IgG autoantibodies.
- To explore FcRn-targeting strategies for treating immunoglobulin G-driven autoimmune diseases.
- To discuss the clinical progress and future directions of FcRn antagonists.
Main Methods:
- Review of existing literature on FcRn biology and its role in autoimmune diseases.
- Analysis of clinical trial data for FcRn antagonists.
- Examination of the structural design and therapeutic landscape of FcRn-targeting agents.
Main Results:
- FcRn antagonism demonstrates efficacy across diverse autoimmune diseases with different pathologies.
- The first FcRn antagonists have gained approval, with numerous next-generation molecules in development.
- FcRn-targeting strategies show potential for both prevalent and rare autoimmune conditions.
Conclusions:
- FcRn antagonists represent a significant advancement in treating IgG-mediated autoimmune diseases.
- This therapeutic class offers new hope for patients with limited or no treatment options.
- FcRn-targeting principles are being explored for broader therapeutic applications beyond autoimmunity.
Related Concept Videos
01:15Transcytosis of IgG
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...